VALN vs. NVAX, MESO, FATE, ALLO, EXAI, ALEC, PROK, TSHA, PRME, and EDIT
Should you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Novavax (NVAX), Mesoblast (MESO), Fate Therapeutics (FATE), Allogene Therapeutics (ALLO), Exscientia (EXAI), Alector (ALEC), ProKidney (PROK), Taysha Gene Therapies (TSHA), Prime Medicine (PRME), and Editas Medicine (EDIT). These companies are all part of the "biological products, except diagnostic" industry.
Valneva (NASDAQ:VALN) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.
Valneva has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, Novavax has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.
11.4% of Valneva shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 0.9% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valneva has higher earnings, but lower revenue than Novavax. Valneva is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
In the previous week, Valneva had 2 more articles in the media than Novavax. MarketBeat recorded 4 mentions for Valneva and 2 mentions for Novavax. Valneva's average media sentiment score of 0.45 beat Novavax's score of 0.44 indicating that Valneva is being referred to more favorably in the media.
Valneva currently has a consensus price target of $21.67, indicating a potential upside of 168.48%. Novavax has a consensus price target of $17.00, indicating a potential upside of 317.69%. Given Novavax's higher probable upside, analysts plainly believe Novavax is more favorable than Valneva.
Novavax has a net margin of -55.41% compared to Valneva's net margin of -65.99%. Novavax's return on equity of 0.00% beat Valneva's return on equity.
Novavax received 819 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 74.29% of users gave Novavax an outperform vote while only 51.16% of users gave Valneva an outperform vote.
Summary
Valneva beats Novavax on 9 of the 17 factors compared between the two stocks.
Get Valneva News Delivered to You Automatically
Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
